Singapore, Singapore

Kantharaj Ethirajulu




Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kantharaj Ethirajulu: Innovator in Anti-Proliferative Agents

Introduction

Kantharaj Ethirajulu is a notable inventor based in Singapore, recognized for his contributions to the field of medicinal chemistry. He holds 2 patents that focus on innovative compounds with potential therapeutic applications. His work primarily revolves around the development of pyrimidine derivatives that serve as anti-proliferative agents.

Latest Patents

Ethirajulu's latest patents include the invention of heteroalkyl linked pyrimidine derivatives. These compounds are designed to be useful as anti-proliferative agents, particularly in the treatment of various proliferative disorders, including tumors and cancers. The patents detail methods for the preparation of these compounds, pharmaceutical compositions containing them, and their applications in treating conditions associated with kinases.

Career Highlights

Kantharaj Ethirajulu is currently associated with S'bio Pte Ltd, where he continues to advance his research in the pharmaceutical field. His work has significant implications for the development of new treatments for serious health conditions.

Collaborations

Ethirajulu collaborates with talented professionals in his field, including Cheng Hsia Angeline Lee and Harish Kumar Mysore Nagaraj. These collaborations enhance the innovative potential of his research and contribute to the advancement of medicinal chemistry.

Conclusion

Kantharaj Ethirajulu is a prominent figure in the development of anti-proliferative agents, with a focus on pyrimidine derivatives. His contributions to the field are paving the way for new therapeutic options in the treatment of proliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…